Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cappella Inc.

This article was originally published in Start Up

Executive Summary

Of the more than one million percutaneous coronary interventions performed in the US last year, approximately 20% of cases involved bifurcations. Even with the advent of drug-eluting stents (DES) as well as dedicated bifurcation stenting systems and creative stenting techniques, lesion histology, patient anatomy, and equipment limitations have frequently led to suboptimal results. Cappella was founded with the goal of improving outcomes in patients with bifurcated lesions.
Advertisement

Related Content

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

MT037410

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel